Inhalant use disorder is a substance use disorder concentrated in adolescents and disproportionately affecting marginalized populations. The substances are legal, cheap, and widely available — making them particularly accessible to younger users with limited resources. The medical risks per use exceed those of most other substances, including the rare possibility of sudden death from a single exposure.
Common inhalants: solvents (glue, paint thinner, gasoline, lighter fluid), aerosols (deodorants, hairsprays, cooking sprays, computer dusters), gases (nitrous oxide whippets, butane lighters, propane, refrigerants), nitrites (amyl nitrite, butyl nitrite — "poppers"). Mechanism varies by substance category — solvents and aerosols produce CNS depression somewhat similar to alcohol; nitrous oxide produces NMDA antagonism; nitrites produce vasodilation and sexual enhancement effects.
The demographic pattern: peak prevalence at ages 14-15 with substantial use among middle and high school students. Decreases with age — most inhalant use does not persist into adulthood, though some patients develop chronic use patterns. Disproportionately affects populations with limited access to other substances and limited adult oversight.
Sudden sniffing death syndrome: the most catastrophic acute risk. Inhalants sensitize the myocardium to catecholamines. Use followed by physical exertion, startle response, or any catecholamine surge can produce fatal cardiac arrhythmia. Death can occur at first use — not a cumulative risk like most other substances. The per-use mortality far exceeds most other recreational drugs.
Chronic medical complications: permanent neurologic damage with chronic heavy use — cerebellar dysfunction, white matter abnormalities (leukoencephalopathy), peripheral neuropathy. Toluene (in glue and paint thinner) is particularly toxic — chronic use produces lasting cerebellar and cognitive impairment. Nitrous oxide chronic use produces B12 deficiency with subacute combined degeneration of spinal cord (motor and sensory deficits). Bone marrow suppression. Hepatotoxicity.
Treatment: no specific pharmacotherapy for inhalant use disorder. Address the underlying social and developmental factors (limited supervision, peer influences, comorbid conditions). Treat acute and chronic medical complications. Behavioral interventions, family involvement, school engagement. Early recognition by parents and educators matters because the per-use risk is high.
Counseling families: watch for signs (chemical odors on breath or clothes, sores or rash around mouth/nose, paint stains on hands, hidden containers, unexplained weakness or confusion). Education in middle schools and high schools. Treatment of comorbid conditions. The window of vulnerability is typically the early-to-middle adolescent years; engaging during that window matters.
When you encounter an adolescent with inhalant use, the conversation includes the unique acute mortality risk. This is not a substance that becomes harmful over years of heavy use; a single episode can kill. The framing matters for the patient and family.